Emles Real Estate Credit ETF (REC)
Delisted
31 Oct 2022
BATS BATS Primary 
CXA $
20. 05
0
0%
$
- Market Cap
- P/E Ratio
0.48% Div Yield
0 Volume
- Eps
$ 20.05
Previous Close Day Range
20.05 20.05
Year Range
20.05 24.89
Want to track REC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Recursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement. End-of-phase 2 meeting with FDA will shed more light on required approval efficacy endpoint for CCM and other trial changes to move forward with, like higher dosing and longer-duration treatment. REC-2282 for Neurofibromatosis Type 2 and REC-4881 for Familial Adenomatous Polyposis are other programs being advanced; Data from each expected Q4 of 2024 and 1st half of 2025 respectively.
Seekingalpha | 1 year ago
